- 24 h
- 7 Tage
- 14 Tage
- 6 Monate
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | Bristol-Myers Squibb Company ÜBERRASCHT Anleger: Folgt jetzt der nächste Kursrutsch? - Dringend vor Montag handeln! | Hebelschein-Spekulant | |||
| Sa | Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle | 5 | The Motley Fool | ||
| Sa | Thousands of Novo Nordisk insulin pens stolen from Dutch wholesaler | 19 | NL Times | ||
| Sa | Sanofi: RBC tritt auf die Bremse - das steckt dahinter | 4 | Maximilian Berger | ||
| Sa | Community Rückblick: BioNTech BNT113 Studie verfehlt Endpunkt: "Die Bude treibt einen zum Wahnsinn!" | 911 | wallstreetONLINE | © Foto: Julia Cebella - dpaBioNTech verfehlt mit BNT113 ein wichtiges Studienziel. Im wO-Forum streiten Anleger über die Zukunft der mRNA-Krebsforschung, die Bewertung der Aktie und das Potenzial der... ► Artikel lesen | |
| Sa | AbbVie: SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 | 1.699 | PR Newswire | 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs
Latest long-term and real-world... ► Artikel lesen | |
| Sa | 17 Prozent Kursverlust nach Studienflop: Syndax stoppt Entwicklung - Mesoblast setzt auf den nächsten GvHD-Markt | Small- & Micro Cap Investment | |||
| Sa | FDA Approves Viatris' RYZUMVI For Presbyopia Treatment | 476 | AFX News | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.RYZUMVI... ► Artikel lesen | |
| Sa | US IPO Weekly Recap: Biotechs City Therapeutics and Iambic headline the week's pricings | 1 | Renaissance Capital | ||
| Sa | Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends | 14 | The Motley Fool | ||
| Fr | Avicanna Inc: Avicanna to transfer U.S. shares to OTCQB | 1 | Stockwatch | ||
| Fr | Avicanna Inc.: Avicanna Transitions US Listing to OTCQB | 4 | GlobeNewswire (USA) | ||
| Fr | NRX Pharmaceuticals, Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| Fr | Iambic Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Cannabis Bioscience International Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| Fr | Canopy Growth Corp - 8-K, Current Report | 20 | SEC Filings | ||
| Fr | TuHURA Biosciences, Inc./NV - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| Fr | Viatris erhält FDA-Zulassung zur Behandlung von Altersweitsichtigkeit | 6 | Investing.com Deutsch | ||
| Fr | Devonian Health Group Inc (2): Devonian Health's NYSE American listing still pending | 2 | Stockwatch |
1 2 3 4 5 Weiter >>
- 24 h
- 7 Tage
- Alle
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| PENTIXAPHARM HOLDING AG | 1,850 | 11,33 | +512 % | 2 | - | - | |||
| DERMAPHARM HOLDING SE | 37,850 | 52 | +37 % | 1 | 3 | - | |||
| BAYER AG | 44,460 | 60,42 | +36 % | 13 | 2 | - | |||
| SANOFI SA | 71,93 | 92,15 | +28 % | 16 | 13 | - | |||
| ASTRAZENECA PLC | 147,10 | 185,57 | +26 % | 38 | 3 | 7 | |||
| GSK PLC | 22,070 | 25,12 | +14 % | 9 | 14 | 8 | |||
 | NOVO NORDISK A/S | 34,555 | 36,37 | +5 % | - | 22 | 8 | ||
| MERCK KGAA | 144,30 | 147,20 | +2 % | 3 | 11 | - | |||
| SCHOTT PHARMA AG & CO KGAA | 24,600 | 24,41 | -1 % | 7 | 2 | - | |||
| PFIZER INC | 26,280 | 25,39 | -3 % | 4 | 7 | - | |||
| ROCHE HOLDING AG PS | 406,39 | 388,53 | -4 % | 7 | 7 | 2 | |||
| NOVARTIS AG | 134,10 | 127,49 | -5 % | 7 | 20 | 2 | |||
| DOCMORRIS AG | 16,720 | 13,23 | -21 % | 6 | 6 | - |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.